FFinance

Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows

  • bytady
  • December 20, 2024
  • 1 minute read
Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows
0
Shares
0
0
0
0

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Jaime Grajales Benjumea—Getty Images

0 Shares:
Share 0
Tweet 0
Pin it 0

Leave a Reply

Your email address will not be published. Required fields are marked *

— Previous article

What Is The Ford B-150, And Can You Buy One In The United States?

Next article —

How to Build a Crypto Mining Rig? Bitcoin Mining in 2023 | by Ankit Gupta | BuyUcoin Talks

You May Also Like
10 Factors for Your Privacy
Read More
  • 4 minute read
FFinance

10 Factors for Your Privacy

By Alexander Linton   The Encryption Conundrum: Hacktivism’s Pursuit of Fully Untraceable Messaging in the Digital Surveillance Era …